The Food and Drugs Authority of Ghana has on today, Monday February 1, 2021 approved a herbal medicine – Cryptolepis sanguinolenta, locally known as ‘Nibima’ for clinical trials in the attempt to find treatment for the ongoing COVID-19 pandemic.
This stamp of approval was issued following the submission of a clinical trial application in by researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology (KNUST) in September 2020 to assess the safety and efficacy of the Cryptolepis sanguinolenta as a potential treatment for combating COVID-19.
And subsequent to results from laboratories studies conducted by the KNUST research team the outcome points in the direction clinical benefits.
The aforementioned research team has over the years been involved in the FDA’s stakeholder engagements and capacity building activities and has an in-depth experience as well as the knowledge in international and national regulatory requirements requisite for the effective conduct of clinical trials; and it is anticipated that data from this study may be useful to inform policy or be used for scientific judgments and opinions pertaining to COVID-19.
However, in its statement signed by the Chief Executive Officer of FDA – Mrs. Delese A.A.Darko, the FDA wishes to reassure the general public that it remains committed to protect the health and safety of consumers.
Below is the press statement released by the Food and Drugs and Authority of Ghana for your read-through.
Ignatius Agyeman Pambour, enmoregh.com